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Background
Pricing and reimbursement authorities often lack sufficient
information to decide about Orphan Medicinal Products
(OMPs), because of pricing, high levels of uncertainty and
small datasets, amongst others. EU Member States share
similar challenges as they seek to include OMPs appropri-
ately in their healthcare systems.
The “Process on Corporate Responsibility in the field of
Pharmaceuticals”, launched in 2010 under the Belgium EU
Presidency, included a project on a “Mechanism of Coor-
dinated Access to Orphan Drugs” (MoCA), to explore
whether a collaborative approach could create opportu-
nities for more timely, sustainable and equitable access to
OMPs. Twelve EU Member States, industry, patients’
representatives and other stakeholders developed a poten-
tial mechanism for such cooperation in the MoCA
Recommendations. EU Member States adopted these as
part of the formal conclusions of the Process on Corporate
Responsibility on 17 April 2013. The Recommendations
identified points where voluntary cooperation could
smooth the process of evaluation, by sharing information
and data along a coordinated, dialogue-based pathway; as
well as a first draft “Transparent Value Framework” (TVF)
to provide a possible structure for national pricing and
reimbursement discussions.
From theory to practice: the MoCA pilot projects
The Medicines Evaluation Committee of the European
Social Insurance Platform (MEDEV) initiated pilot projects
in July 2013. Companies were invited to participate with
OMPs at any stage of development, with the objective of
testing the different elements in the Recommendations.
Sobi signalled its interest to participate.
Seven EU Member States volunteered to join the col-
laboration, together with European Organisation for
Rare Diseases (EURORDIS) and two patient groups
representing the therapeutic area. The participants
agreed potential areas for collaboration, created a
timeline of meeting and topics for shared discussion
(Figure 2), also including other stakeholders.
Sobi’s experience of participating in the MoCA
pilot project
The May 2014 evaluation provided opportunities to
review the MoCA dialogue’s ability to deliver on its
objectives and where more work needs to be done.
Sobi, SE-112 76 Stockholm, Sweden
Figure 1 An example of a proposed Transparent Value Framework
Figure 2 Timeline of MoCA pilot project July 2013-May 2014
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Sobi experienced the MoCA as an important and
highly relevant forum, providing the opportunity for
managed, prospective, multi-stakeholder, trust-based
dialogue, which progressively reduces uncertainty and
allows sponsors to “design-in” payer-driven elements
into development programmes and availability. It is
based on voluntary participation of all participants so
is highly flexible. It gives national payer bodies infor-
mation to help them in their national providing and
reimbursement decisions.
Conclusions
The first pilot was a success in testing the practical
elements of a collaborative dialogue. Further projects
will further test the Recommendations and the MoCA’s
ability to contribute to access to OMPs timely, equitably
and sustainably. The participants in the MoCA pilot
are planning to write up their experiences with an aim to
publish their joint findings to date.
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